SIRT3: Oncogene and tumor suppressor in cancer

Cancers

Volumn 9, Issue 7, 2017, Pages 1-10

  Torrens Mas, Margalida ^a,b,c   Oliver, Jordi ^a,b,c   Roca, Pilar ^a,b,c   Sastre Serra, Jorge ^a,b,c  

^a UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c HEALTH RESEARCH INSTITUTE OF THE BALEARIC ISLANDS IDISBA   (Spain)

Author keywords

Antioxidant enzymes; Cancer; Mitochondria; ROS; SIRT3

Indexed keywords

ISOCITRATE DEHYDROGENASE; MANGANESE SUPEROXIDE DISMUTASE; REACTIVE OXYGEN METABOLITE; SIRTUIN 3;

CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; MALIGNANT NEOPLASM; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; NONHUMAN; ONCOGENE; OXIDATIVE STRESS; PERSONALIZED MEDICINE; RESPIRATORY CHAIN; REVIEW; TUMOR PROMOTION; TUMOR SUPPRESSOR GENE;

EID: 85025695985     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers9070090     Document Type: Review

References (93)

1. Haigis, M.C., Deng, C.-X., Finley, L.W.S., Kim, H.-S., Gius, D. SIRT3 is a mitochondrial tumor suppressor: A scientific tale that connects aberrant cellular ROS, the Warburg effect, and carcinogenesis. Cancer Res. 2012, 72, 2468-2472.
2. Sack, M.N., Finkel, T. Mitochondrial metabolism, sirtuins, and aging. Cold Spring Harbor Perspect. Biol. 2012, 4.
3. Michan, S., Sinclair, D. Sirtuins in mammals: Insights into their biological function. Biochem. J. 2007, 404, 1-13.
4. Alhazzazi, T.Y., Kamarajan, P., Verdin, E., Kapila, Y.L. SIRT3 and cancer: Tumor promoter or suppressor? Biochim. Biophys. Acta 2011, 1816, 80-88.
5. Hirschey, M.D., Shimazu, T., Huang, J.-Y., Schwer, B., Verdin, E. SIRT3 regulates mitochondrial protein acetylation and intermediary metabolism. Cold Spring Harbor Symp. Quant. Biol. 2011, 76, 267-277.
6. Verdin, E., Hirschey, M.D., Finley, L.W.S., Haigis, M.C. Sirtuin regulation of mitochondria: Energy production, apoptosis, and signaling. Trends Biochem. Sci. 2010, 35, 669-675.
7. Scher, M.B., Vaquero, A., Reinberg, D. SirT3 is a nuclear NAD +-dependent histone deacetylase that translocates to the mitochondria upon cellular stress. Genes Dev. 2007, 21, 920-928.
8. Schwer, B., North, B.J., Frye, R.A., Ott, M., Verdin, E. The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase. J. Cell Biol. 2002, 158, 647-657.
9. Cooper, H.M., Huang, J.-Y., Verdin, E., Spelbrink, J.N. A new splice variant of the mouse SIRT3 gene encodes the mitochondrial precursor protein. PLoS ONE 2009, 4.
10. Iwahara, T., Bonasio, R., Narendra, V., Reinberg, D. SIRT3 functions in the nucleus in the control of stress-related gene expression. Mol. Cell. Biol. 2012, 32, 5022-5034.
11. Anderson, K.A., Hirschey, M.D. Mitochondrial protein acetylation regulates metabolism. Essays Biochem. 2012, 52, 23-35.
12. Murphy, M.P. How mitochondria produce reactive oxygen species. Biochem. J. 2009, 417, 1-13.
13. Laurent, A., Nicco, C., Chéreau, C., Goulvestre, C., Alexandre, J., Alves, A., Lévy, E., Goldwasser, F., Panis, Y., Soubrane, O., et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res. 2005, 65, 948-956.
14. Kongara, S., Karantza, V. The interplay between autophagy and ROS in tumorigenesis. Front. Oncol. 2012, 2, 171.
15. Waris, G., Ahsan, H. Reactive oxygen species: Role in the development of cancer and various chronic conditions. J. Carcinog. 2006, 5, 14.
16. Sainz, R.M., Lombo, F., Mayo, J.C. Radical decisions in cancer: Redox control of cell growth and death. Cancers 2012, 4, 442-474.
17. Pelicano, H., Carney, D., Huang, P. ROS stress in cancer cells and therapeutic implications. Drug Resist. Updat. 2004, 7, 97-110.
18. Kim, H.S., Patel, K., Muldoon-Jacobs, K., Bisht, K.S., Aykin-Burns, N., Pennington, J.D., van der Meer, R., Nguyen, P., Savage, J., Owens, K.M., et al. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 2010, 17, 41-52.
19. Valko, M., Izakovic, M., Mazur, M., Rhodes, C.J., Telser, J. Role of oxygen radicals in DNA damage and cancer incidence. Mol. Cell. Biochem. 2004, 266, 37-56.
20. Choudhary, C., Kumar, C., Gnad, F., Nielsen, M.L., Rehman, M., Walther, T.C., Olsen, J.V., Mann, M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325, 834-840.
21. Kim, S.C., Sprung, R., Chen, Y., Xu, Y., Ball, H., Pei, J., Cheng, T., Kho, Y., Xiao, H., Xiao, L., et al. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol. Cell. 2006, 23, 607-618.
22. Hallows, W.C., Albaugh, B.N., Denu, J.M. Where in the cell is SIRT3?—Functional localization of an NAD+-dependent protein deacetylase. Biochem. J. 2008, 411.
23. Buler, M., Aatsinki, S.-M., Izzi, V., Hakkola, J. Metformin reduces hepatic expression of SIRT3, the mitochondrial deacetylase controlling energy metabolism. PLoS ONE 2012, 7, e49863.
24. Wang, Q., Li, L., Li, C.Y., Pei, Z., Zhou, M., Li, N. SIRT3 protects cells from hypoxia via PGC-1α-and MnSOD-dependent pathways. Neuroscience 2015, 286, 109-121.
25. Desouki, M.M., Doubinskaia, I., Gius, D., Abdulkadir, S.A. Decreased mitochondrial SIRT3 expression is a potential molecular biomarker associated with poor outcome in breast cancer. Hum. Pathol. 2014, 45.
26. Ashraf, N., Zino, S., Macintyre, A., Kingsmore, D., Payne, P., George, W.D., Shiels, P.G. Altered sirtuin expression is associated with node-positive breast cancer. Br. J. Cancer. 2006, 95, 1056-1061.
27. He, S., He, C., Yuan, H., Xiong, S., Xiao, Z., Chen, L. The SIRT3 expression profile is associated with pathological and clinical outcomes in human breast cancer patients. Cell Physiol. Biochem. 2014, 34, 2061-2069.
28. Chen, Y., Fu, L.L., Wen, X., Wang, X.Y., Liu, J., Cheng, Y., Huang, J. Sirtuin-3 (SIRT3), a therapeutic target with oncogenic and tumor-suppressive function in cancer. Cell Death Dis. 2014, 5, e1047.
29. Zhang, L., Ren, X., Cheng, Y., Huber-Keener, K., Liu, X., Zhang, Y., Yuan, Y.-S., Yang, J.-W., Liu, C.-G., Yang, J.-M. Identification of Sirtuin 3, a mitochondrial protein deacetylase, as a new contributor to tamoxifen resistance in breast cancer cells. Biochem. Pharmacol. 2013, 86, 726-733.
30. Liu, C., Huang, Z., Jiang, H., Shi, F. The Sirtuin 3 expression profile is associated with pathological and clinical outcomes in colon cancer patients. Biomed. Res. Int. 2014, 2014, 87126.
31. Sastre-Serra, J., Nadal-Serrano, M., Pons, D.G., Valle, A., Garau, I., Garcia-Bonafe, M, Oliver, J., Roca, P. The oxidative stress in breast tumors of postmenopausal women is ERalpha/ERbeta ratio dependent. Free Radic. Biol. Med. 2013, 61, 11-17.
32. Torrens-Mas, M., Roca, P., Sastre-Serra, J. Role of sirtuin 3 in oxidative stress and cancer. Med. Balear 2017, 32, 47-52.
33. Park, S.-H., Ozden, O., Jiang, H., Cha, Y.I., Pennington, J.D., Aykin-Burns, N., Spitz, D.R., Gius, D., Kim, H.-S. Sirt3, mitochondrial ROS, ageing, and carcinogenesis. Int. J. Mol. Sci. 2011, 12, 6226-6239.
34. Alhazzazi, T.Y., Kamarajan, P., Verdin, E., Kapila, Y. Sirtuin-3 (SIRT3) and the hallmarks of cancer. Genes Cancer 2013, 4, 164-171.
35. Finley, L.W.S., Carracedo, A., Lee, J., Souza, A., Egia, A., Zhang, J., Teruya-Feldstein, J., Moreira, P.I., Cardoso, S.M., Clish, C.B., et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization. Cancer Cell 2011, 19, 416-428.
36. Bell, E.L., Emerling, B.M., Ricoult, S.J.H., Guarente, L. SirT3 suppresses hypoxia inducible factor 1α and tumor growth by inhibiting mitochondrial ROS production. Oncogene 2011, 30, 2986-2996.
37. Schlicker, C., Gertz, M., Papatheodorou, P., Kachholz, B., Becker, C.F.W., Steegborn, C. Substrates and regulation mechanisms for the human mitochondrial sirtuins Sirt3 and Sirt5. J. Mol. Biol. 2008, 382, 790-801.
38. Tao, R., Coleman, M.C., Pennington, J.D., Ozden, O., Park, S.-H., Jiang, H., Kim, H.-S., Flynn, C.R., Hill, S., McDonald, W.H., et al. Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol. Cell 2010, 40, 893-904.
39. Bause, A.S., Haigis, M.C. SIRT3 regulation of mitochondrial oxidative stress. Exp. Gerontol. 2013, 48, 634-639.
40. Zhu, Y., Yan, Y., Principe, D.R., Zou, X., Vassilopoulos, A., Gius, D. SIRT3 and SIRT4 are mitochondrial tumor suppressor proteins that connect mitochondrial metabolism and carcinogenesis. Cancer Metab. 2014, 2.
41. Ozden, O., Park, S.H., Kim, H.S., Jiang, H., Coleman, M.C., Spitz, D.R., Gius, D. Acetylation of MnSOD directs enzymatic activity responding to cellular nutrient status or oxidative stress. Aging 2011, 3, 102-107.
42. Zou, X., Santa-Maria, C.A., O’Brien, J., Gius, D., Zhu, Y. Manganese superoxide dismutase acetylation and dysregulation, due to loss of SIRT3 activity, promote a Luminal B-like breast carcinogenic-permissive phenotype. Antioxid. Redox Signal. 2016, 25, 326-336.
43. Someya, S., Yu, W., Hallows, W.C., Xu, J., Vann, J.M., Leeuwenburgh, C., Tanokura, M., Denu, J.M., Prolla, T.A. Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell 2010, 143, 802-812.
44. Sundaresan, N.R., Gupta, M., Kim, G., Rajamohan, S.B., Isbatan, A., Gupta, M.P. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J. Clin. Investig. 2009, 119, 2758-2771.
45. Weir, H.J.M., Lane, J.D., Balthasar, N. SIRT3: A central regulator of mitochondrial adaptation in health and disease. Genes Cancer 2013, 4, 118-124.
46. Torrens-Mas, M., Pons, D.G., Sastre-Serra, J., Oliver, J., Roca, P. SIRT3 silencing sensitizes breast cancer cells to cytotoxic treatments through an increment in ROS production. J. Cell. Biochem. 2016, 10, 1-10.
47. Tseng, A.H.H., Shieh, S.S., Wang, D.L. SIRT3 deacetylates FOXO3 to protect mitochondria against oxidative damage. Free Radic. Biol. Med. 2013, 63, 222-234.
48. Rangarajan, P.P., Karthikeyan, A., Lu, J., Ling, E.-A., Dheen, S.T. Sirtuin 3 regulates Foxo3a-mediated antioxidant pathway in microglia. Neuroscience 2015, 311, 398-414.
49. Huang, J.-Y., Hirschey, M.D., Shimazu, T., Ho, L., Verdin, E. Mitochondrial sirtuins. Biochim. Biophys. Acta Proteins Proteomics 2010, 1804, 1645-1651.
50. Ahn, B.-H., Kim, H.-S., Song, S., Lee, I.H., Liu, J., Vassilopoulos, A., Deng, C.-X., Finkel, T. A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc. Natl. Acad. Sci. USA 2008, 105, 14447-14452.
51. Wei, L., Zhou, Y., Dai, Q., Qiao, C., Zhao, L., Hui, H., Lu, N., Gio, L.-Q. Oroxylin A induces dissociation of hexokinase II from the mitochondria and inhibits glycolysis by SIRT3-mediated deacetylation of cyclophilin D in breast carcinoma. Cell Death Dis. 2013, 4, e601.
52. Hallows, W.C., Lee, S., Denu, J.M. Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. Proc. Natl. Acad. Sci. USA 2006, 103, 10230-10235.
53. Schwer, B., Bunkenborg, J., Verdin, R.O., Andersen, J.S., Verdin, E. Reversible lysine acetylation controls the activity of the mitochondrial enzyme acetyl-CoA synthetase 2. Proc. Natl. Acad. Sci. USA 2006, 103, 10224-10229.
54. Shan, C., Kang, H.B., Elf, S., Xie, J., Gu, T.L., Aguiar, M., Lonning, S., Hitosugi, T., Chung, T.-W., Arellano, M., et al. Tyr-94 phosphorylation inhibits pyruvate dehydrogenase phosphatase 1 and promotes tumor growth. J. Biol. Chem. 2014, 289, 21413-21422.
55. Cui, Y., Qin, L., Wu, J., Qu, X., Hou, C., Sun, W., Li, S., Vaughan, A.T.M., Li, J.J., Liu, J. SIRT3 enhances glycolysis and proliferation in SIRT3-expressing gastric cancer cells. PLoS ONE 2015, 10, e0129834.
56. Hirschey, M.D., Shimazu, T., Goetzman, E., Jing, E., Schwer, B., Lombard, D.B., Grueter, C.A., Harris, C., Biddinger, S.O., Ilkayeva, R. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 2010, 464, 121-125.
57. Shimazu, T., Hirschey, M.D., Hua, L., Dittenhafer-Reed, K.E., Schwer, B., Lombard, D.B., Li, Y., Bunkenborg, J., Alt, F.W., Denu, J.M., et al. SIRT3 deacetylates mitochondrial 3-hydroxy-3-methylglutaryl CoA synthase 2 and regulates ketone body production. Cell Metab. 2010, 12, 654-661.
58. Choi, J., Koh, E., Lee, Y.S., Lee, H.-W., Kang, H.G., Yoon, Y.E., Hanb, W.K., Choic, K.H., Kimet, K.-S. Mitochondrial Sirt3 supports cell proliferation by regulating glutamine-dependent oxidation in renal cell carcinoma. Biochem. Biophys. Res. Commun. 2016, 474, 547-553.
59. Allows, W.C., Yu, W., Smith, B.C., Devires, M.K., Ellinger, J.J., Someya, S., Shortreed, M.R., Prolla, T., Markley, J.L., Smith, L.M., et al. Sirt3 promotes the urea cycle and fatty acid oxidation during dietary restriction. Mol. Cell 2011, 41, 139-149.
60. Cimen, H., Han, M.J., Yang, Y., Tong, Q., Koc, H., Koc, E.C. Regulation of succinate dehydrogenase activity by SIRT3 in mammalian mitochondria. Biochemistry 2010, 49, 304-311.
61. Finley, L.W.S., Haas, W., Desquiret-Dumas, V., Wallace, D.C., Procaccio, V., Gygi, S.P., Haigis, M.C. Succinate dehydrogenase is a direct target of sirtuin 3 deacetylase activity. PLoS ONE 2011, 6, 4-9.
62. Jing, E., Emanuelli, B., Hirschey, M.D., Boucher, J., Lee, K.Y., Lombard, D., Haigis, M.C. Sirtuin-3 (Sirt3) regulates skeletal muscle metabolism and insulin signaling via altered mitochondrial oxidation and reactive oxygen species production. Proc. Natl. Acad. Sci. USA 2011, 108, 14608-14613.
63. Abdel Khalek, W., Cortade, F., Ollendorff, V., Lapasset, L., Tintignac, L., Chabi, B., Verdin, E.M., Kahn, C.R. SIRT3, a mitochondrial NAD +-dependent deacetylase, is involved in the regulation of myoblast differentiation. PLoS ONE 2014, 9, e114388.
64. Wu, Y., Lee, H., Liao, C., Wei, Y. Regulation of mitochondrial FoF1ATPase activity by Sirt3-catalyzed deacetylation and its de ficiency in human cells harboring 4977 bp deletion of mitochondrial DNA. BBA Mol. Basis Dis. 2013, 1832, 216-227.
65. Pillai, V.B., Sundaresan, N.R., Kim, G., Gupta, M., Rajamohan, S.B., Pillai, J.B., Samant, S., Ravindra, P.V., Isbatan, A., Gupta, M.P. Exogenous NAD blocks cardiac hypertrophic response via activation of the SIRT3-LKB1-AMP-activated kinase pathway. J. Biol. Chem. 2010, 285, 3133-3144.
66. Kong, X., Wang, R., Xue, Y., Liu, X., Zhang, H., Chen, Y., Fang, F., Chang, Y. Sirtuin 3, a new target of PGC-1alpha, plays an important role in the suppression of ROS and mitochondrial biogenesis. PLoS ONE 2010, 5.
67. Giralt, A., Hondares, E., Villena, J.A., Ribas, F., Díaz-Delfín, J., Giralt, M., Villarroya, F. Peroxisome proliferator-activated receptor-gamma coactivator-1alpha controls transcription of the Sirt3 gene, an essential component of the thermogenic brown adipocyte phenotype. J. Biol. Chem. 2011, 286, 16958-16966.
68. Shi, T., Wang, F., Stieren, E., Tong, Q. SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. J. Biol. Chem. 2005, 280, 13560-13567.
69. Samant, S.A., Zhang, H.J., Hong, Z., Pillai, V.B., Sundaresan, N.R., Wolfgeher, D., Archerc, S.L., Chanf, D.C., Guptaa, M.P. SIRT3 deacetylates and activates OPA1 to regulate mitochondrial dynamics during stress. Mol. Cell. Biol. 2014, 34, 807-819.
70. Papa, L., Germain, D. SirT3 regulates the mitochondrial unfolded protein response. Mol. Cell. Biol. 2014, 34, 699-710.
71. Hafner, A.V., Dai, J., Gomes, A.P., Xiao, C.Y., Palmeira, K.C.M., Rosenzweig, A. Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy. Aging (Albany. NY). 2010, 2, 914-923.
72. Cheng, Y., Ren, X., Gowda, S.P., Shan, Y., Zhang, L., Yuan, Y.-S., Patel, R., Wu, H., Huber-Keener, K., Yang, J.W., et al. Interaction of Sirt3 with OGG1 contributes to repair of mitochondrial DNA and protects from apoptotic cell death under oxidative stress. Cell Death Dis. 2013, 4, e731.
73. Ward, P.S., Thompson, C.B. Metabolic reprogramming: A cancer hallmark even warburg did not anticipate. Cancer Cell 2012, 21, 297-308.
74. Warburg, O. On the origin of cancer cells. Science 1956, 123, 309-314.
75. Ferreira, L.M.R. Cancer metabolism: The Warburg effect today. Exp. Mol. Pathol. 2010, 89, 372-380.
76. Hanahan, D., Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646-674.
77. DeBerardinis, R.J., Lum, J.J., Hatzivassiliou, G., Thompson, C.B. The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008, 7, 11-20.
78. Heiden, M.G., Cantley, L.C., Thompson, C.B., Mammalian, P., Exhibit, C., Metabolism, A. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 2009, 324, 1029-1034.
79. Sundaresan, N.R., Samant, S.A., Pillai, V.B., Rajamohan, S.B., Gupta, M.P. SIRT3 is a stress-responsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of Ku70. Mol. Cell. Biol. 2008, 28, 6384-6401.
80. Li, S., Banck, M., Mujtaba, S., Zhou, M.M., Sugrue, M.M., Walsh, M.J. p53-Induced growth arrest is regulated by the Mitochondrial SirT3 deacetylase. PLoS ONE 2010, 5, 1-12.
81. Zhao, Y., Yang, H., Wang, X., Zhang, R., Wang, C., Guo, Z. Sirtuin-3 (SIRT3) expression is associated with overall survival in esophageal cancer. Ann. Diagn. Pathol. 2013, 17, 483-485.
82. Alhazzazi, T.Y., Kamarajan, P., Joo, N., Huang, J.-Y., Verdin, E., D’Silva, N.J. Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer 2011, 117, 1670-1678.
83. George, J., Nihal, M., Singh, C.K., Zhong, W., Liu, X., Ahmad, N. Pro-proliferative function of mitochondrial sirtuin deacetylase SIRT3 in human melanoma. J. Investig. Dermatol. 2016, 136, 809-818.
84. Allison, S.J., Milner, J. SIRT3 is pro-apoptotic and participates in distinct basal apoptotic pathways. Cell Cycle 2007, 6, 2669-2677.
85. Marfe, G., Tafani, M., Indelicato, M., Sinibaldi-Salimei, P., Reali, V., Pucci, B., Fini, M., Russo, M.A. Kaempferol induces apoptosis in two different cell lines via Akt inactivation, Bax and SIRT3 activation, and mitochondrial dysfunction. J. Cell. Biochem. 2009, 106, 643-650.
86. Liu, Y., Liu, Y.-L., Cheng, W., Yin, X.-M., Jiang, B. The expression of SIRT3 in primary hepatocellular carcinoma and the mechanism of its tumor suppressing effects. Eur. Rev. Med. Pharmacol. Sci. 2017, 21, 978-998.
87. Zhang, B., Qin, L., Zhou, C.J., Liu, Y.L., Qian, H.X., He, S.B. SIRT3 expression in hepatocellular carcinoma and its impact on proliferation and invasion of hepatoma cells. Asian Pac. J. Trop. Med. 2013, 6, 649-652.
88. Wang, J.-X., Yi, Y., Li, Y.-W., Cai, X.-Y., He, H.-W., Ni, X.-C., Zhou, J., Cheng, Y.-F., Jin, J.-J., Fan, J., et al. Down-regulation of sirtuin 3 is associated with poor prognosis in hepatocellular carcinoma after resection. BMC Cancer 2014, 14, 297.
89. Yu, W., Denu, R.A., Krautkramer, K.A., Grindle, K.M., Yang, D.T., Asimakopoulos, F., Hematti, P., Denu, J.M. Loss of SIRT3 provides growth advantage for B-cell malignancies. J. Biol. Chem. 2016, 291, 3268-3279.
90. Dong, X.C., Jing, L.M., Wang, W.X., Gao, Y.X. Down-regulation of SIRT3 promotes ovarian carcinoma metastasis. Biochem. Biophys. Res. Commun. 2016, 475, 245-250.
91. Zhang, Y.Y., Zhou, L.M. SIRT3 inhibits hepatocellular carcinoma cell growth through reducing Mdm2-mediated p53 degradation. Biochem. Biophys. Res. Commun. 2012, 423, 26-31.
92. Sullivan, L.B., Chandel, N.S. Mitochondrial reactive oxygen species and cancer. Cancer Metab. 2014, 2, 17.
93. Galadari, S., Rahman, A., Pallichankandy, S., Thayyullathil, F. Reactive oxygen species and cancer paradox: To promote or to suppress? Free Radic. Biol. Med. 2017, 104, 144-164.